Suppr超能文献

非撕除后弹力层的角膜内皮移植术治疗疑难病例:病例系列。

Non stripping descemet membrane endothelial keratoplasty in difficult cases: A case series.

机构信息

Hôpital Fondation Ophtalmologique Adolphe-de-Rothschild, 29, rue Manin, 75019 Paris, France.

Hôpital Fondation Ophtalmologique Adolphe-de-Rothschild, 29, rue Manin, 75019 Paris, France.

出版信息

J Fr Ophtalmol. 2021 May;44(5):687-692. doi: 10.1016/j.jfo.2020.07.024. Epub 2021 Mar 19.

Abstract

Endothelial keratoplasty (EK) has been increasingly used instead of penetrating keratoplasty (PK) in the management of post PK graft rejection. Both DSAEK and DMEK involve the surgical removal of the diseased host endothelial cell layer and Descemet's membrane (DM) (descemetorhexis) before transplantation, a technically challenging step, especially in post-PK eyes. Understandably, interest arose when non-stripping DMEK (nDMEK) was described in 2013, and recent studies suggested encouraging results without increased early postoperative failures or complications requiring rebubbling. The purpose of our series was to further study the feasibility and safety of nDMEK and to compare the results with traditional DMEK. This is a single center case series of 3 eyes which underwent nDMEK performed by experienced surgeons (C.P, A.M). Two eyes had nDMEK as a secondary procedure following a failed/rejected PK, while the third case underwent nDMEK on a virgin eye. Undiseased donor DM and a regular host endothelium were required to be eligible for nDMEK. The average change in CCT at last follow-up was -21.2% (±13.3). All required intracameral air injection (rebubbling) within the first few days, with a mean of 2.33 rebubblings per eye, the first one occurring at 6.33±2.52 days after surgery. Non-stripping DMEK surgery appears to be a feasible option, and results are satisfactory at mid to long term. However, in our series, the immediate postoperative period was marked by an increased rebubbling rate. While foreseeable particularly in high-risk cases, surgeons considering this technique should expect a higher risk of early rejection.

摘要

内皮角膜移植术(EK)已越来越多地用于治疗穿透性角膜移植术后(PK)移植物排斥反应,而非穿透性角膜移植术(PK)。无论是 DSAEK 还是 DMEK,在移植前都需要通过手术去除病变的宿主内皮细胞层和 Descemet 膜(DM)(撕囊),这是一个具有挑战性的技术步骤,尤其是在 PK 术后的眼睛中。可以理解的是,当 2013 年描述了非剥脱性 DMEK(nDMEK)时,人们产生了兴趣,最近的研究表明,nDMEK 具有令人鼓舞的结果,没有增加早期术后失败或需要再次注气的并发症。我们的系列研究旨在进一步研究 nDMEK 的可行性和安全性,并将结果与传统 DMEK 进行比较。这是一项由经验丰富的外科医生(C.P、A.M)进行的 3 只眼的单中心病例系列研究。2 只眼是在失败/排斥的 PK 后进行 nDMEK 的二次手术,而第 3 例是在正常的眼睛上进行 nDMEK。nDMEK 需要供体 DM 无病变且宿主内皮正常。最后一次随访时 CCT 的平均变化为-21.2%(±13.3)。所有眼都需要在最初几天内进行房内空气注射(再次注气),每只眼平均需要 2.33 次再次注气,第一次发生在术后 6.33±2.52 天。非剥脱性 DMEK 手术似乎是一种可行的选择,中期至长期结果令人满意。然而,在我们的系列研究中,术后即刻期的再次注气率增加。尽管在高风险病例中可以预见,但考虑采用这种技术的外科医生应该预期早期排斥的风险更高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验